Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001701541-24-000042
Filing Date
2024-11-05
Accepted
2024-11-05 07:03:50
Documents
67
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q bdtx-20240930.htm   iXBRL 10-Q 928050
2 EX-10.11 separationagreement-ni.htm EX-10.11 49815
3 EX-10.12 employmentagreement-jones.htm EX-10.12 111587
4 EX-31.1 exhibit311_q32024.htm EX-31.1 12498
5 EX-31.2 exhibit312_q32024.htm EX-31.2 12368
6 EX-32.1 exhibit321_q32024.htm EX-32.1 9418
12 GRAPHIC image_0.jpg GRAPHIC 5700
  Complete submission text file 0001701541-24-000042.txt   5203900

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bdtx-20240930.xsd EX-101.SCH 29864
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bdtx-20240930_cal.xml EX-101.CAL 52999
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bdtx-20240930_def.xml EX-101.DEF 120055
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bdtx-20240930_lab.xml EX-101.LAB 505649
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bdtx-20240930_pre.xml EX-101.PRE 331180
70 EXTRACTED XBRL INSTANCE DOCUMENT bdtx-20240930_htm.xml XML 629240
Mailing Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142 617-417-5868
Black Diamond Therapeutics, Inc. (Filer) CIK: 0001701541 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39200 | Film No.: 241425591
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)